istock-487636172
marianvejcik / iStockphoto.com
20 October 2017Big Pharma

Alnylam faces declaratory relief claim over SPCs

Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates (SPCs) requested by biotech company Silence Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
7 July 2017   Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.
article
11 December 2018   UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Americas
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

More on this story

Europe
7 July 2017   Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.
article
11 December 2018   UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Americas
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

More on this story

Europe
7 July 2017   Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.
article
11 December 2018   UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Americas
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.